CPIX CUMBERLAND PHARMACEUTICALS INC

Nasdaq cumberlandpharma.com


$ 2.19 $ 0.21 (10.55 %)    

Tuesday, 11-Nov-2025 12:57:24 EST
QQQ $ 621.27 $ 0.65 (0.1 %)
DIA $ 478.90 $ 4.79 (1.01 %)
SPY $ 682.72 $ 2.75 (0.4 %)
TLT $ 89.97 $ 0.03 (0.04 %)
GLD $ 378.13 $ -1.74 (-0.46 %)
$ 1.98
$ 1.99
$ 2.16 x 52
$ 2.25 x 66
$ 2.00 - $ 2.20
$ 1.04 - $ 7.25
86,839
na
29.61M
$ 0.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-08-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 03-07-2025 12-31-2024 10-K
5 11-08-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-10-2024 03-31-2024 10-Q
8 03-13-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-13-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-13-2022 03-31-2022 10-Q
16 03-11-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-22-2020 03-31-2020 10-Q
24 03-20-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 03-12-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-09-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-13-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-13-2016 03-31-2016 10-Q
40 03-14-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cumberland-q3-adj-eps-006-down-from-002-yoy-sales-8292m-down-from-9086m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) ...

Core News & Articles

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapyNASHVILLE, Tenn., Oct. ...

 cumberland-pharma-adds-potent-antibiotic-vibativ-to-national-group-purchasing-agreement-with-premier

Premier Membership includes 4,350 U.S. HospitalsNASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc....

 cumberland-pharmaceuticals-ibuprofen-injection-receives-mexican-regulatory-approval-to-treat-pain-and-fever-pisa-to-roll-out-product-in-mexico

Injectable Ibuprofen Approved for Treating Pain & FeverNASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceu...

 correction-cumberland-q2-adj-eps-002-up-from-001-yoy-sales-10838m-up-from-9849m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.02 per share. This is a 100 percent increase over earnings of $0.01 ...

 cumberland-pharma-announces-availability-of-vibativ-4-vial-starter-pak-through-new-contract-with-vizient

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centersNASHVILLE, Tenn...

 cumberland-pharma-presents-latest-results-from-phase-2-fight-dmd-trial-evaluating-ifetroban-oral-therapy-for-dmd-heart-disease-at-ppmd-conference-in-las-vegas

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce ca...

 cumberland-pharmaceuticals-and-qureight-partner-to-advance-idiopathic-pulmonary-fibrosis-treatment-research

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial

 cumberland-q1-adj-eps-016-up-from-005-yoy-sales-1171m-up-from-850m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.16 per share. This is a 420 percent increase over losses of $(0.05) ...

 cumberland-pharmaceuticals-announced-results-from-its-phase-2-fight-dmd-clinical-trial-were-selected-for-late-breaking-presentation-at-the-muscular-dystrophy-association-clinical--scientific-conference-in-dallas

Ifetroban demonstrated significant 5.4% improvement in cardiac function

 cumberland-q4-adj-eps-002-up-from-011-yoy-sales-1044m-up-from-935m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.02) per share. This is a 81.82 percent increase over losses of $(0.11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION